思美泰治疗慢性病毒性肝炎合并胆汁淤积疗效观察  

Clinical efficacy of Transmetil therapy on chronic virus hepatitis with intra-hepatic cholestasis

作　　者：郑仕君[1] 周比冠[1] 肖飞霞[2] 

机构地区：[1]山东省即墨市人民医院感染性疾病科,山东青岛266200 [2]山东省即墨市人民医院血液净化中心,山东青岛266200

出　　处：《中国医药导报》2011年第9期70-71,共2页China Medical Herald

摘　　要：目的:观察思美泰对慢性病毒性肝炎合并胆汁淤积的疗效。方法:将180例患者随机分为A治疗组、B治疗组、对照组各60例。对照组给予甘草酸二铵、还原型谷胱甘肽、门冬氨酸钾镁、维生素K1综合治疗。在综合治疗的基础上,A治疗组加用思美泰1 000 mg,B治疗组加用思美泰2 000 mg。观察三组治疗前后临床症状、体征及肝功能指标的变化。结果:A治疗组与B治疗组在改善临床症状、体征及肝功能指标方面与对照组比较差异有统计学意义(P<0.05或P<0.01);B治疗组在降低TBIL、GGT、ALP方面与A治疗组比较差异有统计学意义(P<0.05);治疗过程中未发现思美泰相关的不良反应。结论:思美泰治疗慢性病毒性肝炎合并胆汁淤积效果较好,且适当增加剂量可提高疗效,安全性较好。Objective：To explore clinical efficacy of Transmetil therapy on chronic virus hepatitis with intra-hepatic cholestasis.Methods：180 cases with chronic virus hepatitis with intra-hepatic cholestasis were randomly divided into three groups：group A,group B and control group（60 case in each group）,patients in group A received basic treatment plus Transmetil（1 000 mg,once daily）;patients in group B received basic treatment plus Transmetil（2 000 mg,once daily;patients in control group received only basic treatment（diammonium glycyrrhizinate,reduced glutathione,potassium magnesium aspartate,Vitamin K1）.The symptoms,signs and live functions of these patients were observed after treatment.Results：Patients in group A and group B responsed better than patients in control group in terms of improvement of symptoms,signs and live functions（P0.05 or P0.01）.Patients in group B responsed better than patients in group A in terms of reduce in TBIL,GGT,ALP in live functions（P0.05）.No Transmetil related side effects were observed.Conclusion：Clinical efficacy of Transmetil therapy on chronic virus hepatitis with intra-hepatic cholestasis is good,higher dosage of Transmetil can achieve better reponse.

关 键 词：思美泰 慢性病毒性肝炎 胆汁淤积 

分 类 号：R512.6[医药卫生—内科学] R575.6[医药卫生—临床医学]